Cynata will soon move to manufacture world first GMP-grade mesenchymal stem cells (MSCs)

Cynata Therapeutics (formally EcoQuest) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™. A Phase I human clinical trial of the Cymerus™ stem cell technology is currently in planning stage, with discussions underway with regulatory authorities to ascertain and clarify the likely regulatory path for this therapeutic product. Cynata has achieved world first breakthrough in the manufacture of stem cells.

Cymerus™  process differs from other process in the aspect that this process uses induced pluripotent stem cells (iPSCs) which can be generated limitlessly directly from human adult cells and a patent-protected process to derive mesenchymal stem cells (MSCs) for commercial use while existing methods of MSC production require a continuous supply of new tissue donations. This stem cell manufacturing process is capable of producing mesenchymal stem cells (MSCs) for therapeutic application, consistently, efficiently and economically, in a Good Manufacturing Practice (GMP) production environment.  Cynata will now move to manufacture its GMP-grade Cymerus™  MSC product and is now set to scale up manufacturing of its mesenchymal stem cells for therapeutic use. This will clears the path towards low cost, cutting edge cell therapy. Cymerus™  stem cell manufacturing process has now been successfully validated at a key U.S. biomanufacturing site.